Skip to main content

Table 1 The baseline characteristics of the study patients with diabetic macular edema

From: Anatomical and functional responses in eyes with diabetic macular edema treated with “1 + PRN” ranibizumab: one-year outcomes in population of mainland China

Baseline characteristics

n = 69

Mean age of onset, mean ± SD

55.75 ± 12.17 (range, 22–78)

Gender

 Male, no. (%)

41 (59.42)

 Female, no. (%)

28 (40.58)

BCVA (logMAR units), total, mean ± SD

0.64 ± 0.24

 Sub-group of intact EZ

0.61 ± 0.24

 Sub-group of disrupted EZ

0.66 ± 0.22

 Sub-group of intact ELM

0.60 ± 0.24

 Sub-group of disrupted ELM

0.68 ± 0.22

Central foveal thickness (μm), total, mean ± SD

478.23 ± 172.32

 Sub-group of intact EZ

476.56 ± 156.02

 Sub-group of disrupted EZ

480.40 ± 194.21

 Sub-group of intact ELM

481.16 ± 181.04

 Sub-group of disrupted ELM

473.38 ± 160.20

Subfoveal choroidal thickness(μm), mean ± SD

229.55 ± 65.07

Percentage of intraretinal fluid cyst, no. (%)

45 (65.22)

Percentage of subretinal fluid, no. (%)

44 (63.77)

Percentage of disrupted EZ, no. (%)

30 (43.48)

Percentage of disrupted ELM, no. (%)

26 (37.68)

  1. BCVA best-corrected visual acuity, logMAR logarithm of the minimal angle of resolution, EZ epiretinal membrane, ELM external limiting membrane